A new framework reveals why cannabis affects anxiety differently

Beyond the Diagnostic Binary: A Translational Use of the Research Domain Criteria to Improve the Measurement of Anxiety in the Context of Cannabis Use.

Healthcare (Basel, Switzerland) • • Highly Relevant
🤖

AI Summary

This mixed-methods study examined how adults who use cannabis understand and experience anxiety. Among 30 adult cannabis consumers, both medical and recreational groups showed clinically significant anxiety symptoms on the State-Trait Anxiety Inventory. Medical consumers reported using cannabis more frequently—an average of 28.95 days per month, compared with 23.55 days per month among recreational consumers—and were more likely to report elevated anxiety symptoms.

Interviews showed that people’s experiences of anxiety and cannabis were individualized and more nuanced than a simple diagnosis of having or not having an anxiety disorder. The authors propose the Research Domain Criteria (RDoC) framework as a way to study for whom and under what circumstances cannabis may reduce or increase anxiety. For users, the findings underscore that cannabis does not affect anxiety uniformly, while for researchers they suggest that moving beyond binary diagnoses could produce a more informative understanding of cannabis-related outcomes.

💡 Key Findings

1
Both medical and recreational cannabis consumers showed clinically significant anxiety symptoms, with medical consumers more likely to endorse elevated anxiety.
Moderate
55%
2
Medical cannabis consumers reported more frequent use—28.95 days per month on average versus 23.55 days among recreational consumers.
Moderate
50%
3
Interview findings suggested that anxiety and cannabis experiences are individualized and more complex than binary diagnoses capture.
Moderate
55%
4
The RDoC framework may help researchers examine for whom and under what circumstances cannabis reduces or increases anxiety.
Moderate
55%

📄 Original Abstract

Epidemiological data indicate that over half of people who consume cannabis report anxiety reduction as a reason for use. Anxiety is frequently cited as a primary motivation for cannabis use among both medical and recreational consumers. The lifetime prevalence of anxiety disorders in the United States is approximately 34% with more recent data suggesting that the figure may be as high as 43%. Using a mixed methods design, we collected quantitative data through psychosocial assessment tools and demographic questionnaires from a sample of adult cannabis consumers (n = 30). These data were integrated with qualitative findings from semi structured interviews to contextualize consumers' experiences and perceptions related to anxiety and cannabis use. Medical cannabis consumers (n = 19) reported significantly more frequent consumption, averaging 28.95 days per month, as compared to recreational consumers (n = 11), averaging 23.55 days per month. Scores on the State-Trait Anxiety Inventory indicated clinically significant anxiety symptoms in both groups (39.95 for medical; 38.55 for recreational), with medical consumers more likely to endorse elevated anxiety. Qualitative analyses revealed nuanced and individualized interpretations of anxiety that extended beyond traditional binary diagnostic criteria revealing the Research Domain Criteria (RDoC) as a framework to better understand the relationship between anxiety and cannabis use. The value of this work is its use of the RDoC framework to provide a new way to examine the relationship between anxiety and cannabis consumption. Currently the diagnosis of anxiety is binary based on DSM-5-TR criteria. This limitation makes it challenging to study the complex range of outcomes that occur when examining anxiety and cannabis use. Therefore, the opportunity to understand anxiety from a transdiagnostic framework such as RDoC enables researchers to study for whom and under what circumstances cannabis induces and/or reduces anxiety.

Explore More Research

Stay informed about the latest cannabis science.

Your stash, decoded.